{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/vestibular-neuronitis/prescribing-information/promethazine-teoclate/","result":{"pageContext":{"chapter":{"id":"ac9da5a7-a091-516f-a6b1-03ed2d2f7156","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate","depth":2,"htmlHeader":"<!-- begin field 56ab0bb9-4651-4b15-8392-a82c00a57d50 --><h2>Promethazine teoclate</h2><!-- end field 56ab0bb9-4651-4b15-8392-a82c00a57d50 -->","summary":"","htmlStringContent":"<!-- begin item 20ec6661-5aec-4831-a89d-a82c00a57b8e --><!-- end item 20ec6661-5aec-4831-a89d-a82c00a57b8e -->","topic":{"id":"4161326f-3a9d-549b-a377-dc2f2a6f809a","topicId":"d53e1081-ae57-4dcc-8ee8-14e6be6fb3d6","topicName":"Vestibular neuronitis","slug":"vestibular-neuronitis","lastRevised":"Last revised in November 2017","chapters":[{"id":"1371e2f5-4cd3-5674-aae3-79470e21b62b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cb3f7155-69a7-5a7f-b8c1-2a1a113f0070","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a45dcd81-fea0-598a-ba01-782b350ffabd","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06a83e39-ba88-5cb5-872a-7b5e56e06a3c","slug":"changes","fullItemName":"Changes"},{"id":"c9683178-6f5b-5445-a2d4-02d27c379f4b","slug":"update","fullItemName":"Update"}]},{"id":"a9baddc3-bb87-54e7-b6bf-fb890ce8d86d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"65c0b807-ad55-5cb6-8ac0-1beaf353fd29","slug":"goals","fullItemName":"Goals"},{"id":"c577b7a6-4f03-5974-a443-32000f43d67c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"300cd325-7e03-5d62-afb6-803945166705","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e3892d6-0403-52e9-a509-fc65bd12340b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c67ef3c1-dad6-5fbc-9fc2-1f9ef2f8fcef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e83fe4f4-878e-59eb-a20b-f35218ed5023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4fd633a-c05b-5b41-9dc2-d862bc4286b5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8ab4ebcd-03e4-5892-9e29-aabb20cb8f45","slug":"definition","fullItemName":"Definition"},{"id":"552f3d90-3666-593b-b806-28115dcd8f3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1966c14e-e128-5b21-bbce-6b9d4f48924d","slug":"complications","fullItemName":"Complications"},{"id":"f30ad763-2643-586e-9d19-cffd5f45d021","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"adbff71b-d255-5959-953d-3b2788094c8b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"081f5ce9-172b-5beb-9ace-bbe7a9e86705","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ba7e323e-e894-5821-9164-ea7cd07a38b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7c05a5c3-6c86-5daa-aed5-df8280f3723a","fullItemName":"Management","slug":"management","subChapters":[{"id":"f6abc1bb-cef0-5ec3-abe6-ca99c3f79fa7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"1ae90a52-6113-534c-8cf7-46d78bb039a3","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"354fa7f8-799b-53ab-900a-b4083df52ec8","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"4df87a4b-4d5c-56b0-b766-c143a60b38e8","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"ac9da5a7-a091-516f-a6b1-03ed2d2f7156","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"9f00019c-78be-54da-b9cb-69c6c04c5063","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c39d54c3-45ec-52b9-9dd2-efc3f3caa200","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"d04e0140-1610-5826-9319-63f03c35c2d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"763af5f7-891e-5c76-9970-ae093e35ae7b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d0088dd9-7199-53a5-a4d0-e4299a54c061","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c9ae115f-4e3a-5af0-870e-16c967836515","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"27450791-3a41-5a8d-951b-efe744ca7944","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49115179-8551-5f4b-9d71-06a60c3445da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"051b2f52-2cfa-5527-952f-08a3be08f529","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field c2820322-894f-42e9-bc5c-a82c00a59701 --><h3>What dosage of promethazine teoclate should I prescribe?</h3><!-- end field c2820322-894f-42e9-bc5c-a82c00a59701 -->","summary":"","htmlStringContent":"<!-- begin item 77c6b699-3208-4c03-af33-a82c00a59433 --><!-- begin field 0c7d7387-ca44-4c64-ab8e-a82c00a59701 --><ul><li>Prescribe promethazine teoclate 25 mg orally at night. The dose may be increased to 100 mg daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">MHRA, 2017</a>].  </li></ul><!-- end field 0c7d7387-ca44-4c64-ab8e-a82c00a59701 --><!-- end item 77c6b699-3208-4c03-af33-a82c00a59433 -->","subChapters":[]},{"id":"12f06c0d-7c5a-5372-a20e-2c88180e3ea7","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 26a8dbb3-b7fb-4cb0-98e2-a82c00a5b906 --><h3>What are the contraindications and cautions when prescribing promethazine teoclate?</h3><!-- end field 26a8dbb3-b7fb-4cb0-98e2-a82c00a5b906 -->","summary":"","htmlStringContent":"<!-- begin item 76e676a3-12e3-41da-9763-a82c00a5b756 --><!-- begin field 016a49e1-8420-4a50-a7e0-a82c00a5b906 --><ul><li><strong>Promethazine teoclate should not be used in people with:</strong><ul><li>Hypersensitivity to promethazine, its excipients, or other phenothazines.</li><li>Central nervous system (CNS) depression of any cause.</li><li>Exposure to monoamine oxidase inhibitors within the previous 14 days.</li><li>Severe liver disease — increased risk of coma.</li></ul></li><li><strong>Promethazine teoclate should be used with caution in people with:</strong><ul><li>Hepatic or renal impairment.</li><li>Severe coronary artery disease.</li><li>Urinary retention or prostatic hypertrophy.</li><li>Angle-closure glaucoma.</li><li>Pyloroduodenal obstruction.</li><li>Epilepsy.</li><li>Asthma, bronchitis, or bronchiectasis — promethazine teoclate may thicken or dry lung secretions and impair expectoration.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">MHRA, 2017</a>]</p><!-- end field 016a49e1-8420-4a50-a7e0-a82c00a5b906 --><!-- end item 76e676a3-12e3-41da-9763-a82c00a5b756 -->","subChapters":[]},{"id":"5218a130-6d92-55b2-ac2a-bdf09543b06c","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 9f4fd0ef-171b-436b-bfbb-a82c00a5cf46 --><h3>What are the adverse effects of promethazine teoclate?</h3><!-- end field 9f4fd0ef-171b-436b-bfbb-a82c00a5cf46 -->","summary":"","htmlStringContent":"<!-- begin item ef6c7372-2394-44b7-b5c5-a82c00a5cd9a --><!-- begin field 83da138b-f44e-4b06-8871-a82c00a5cf46 --><p><strong>Adverse effects of promethazine include:</strong></p><ul><li>Neurological — dizziness, confusion, restlessness, headaches, nightmares, sedation (affected people should not drive or operate heavy machinery), tremor, muscle spasms and tic-like movements of the head and face, extrapyramidal effects.</li><li>Antimuscarinic effects — blurred vision, dry mouth, and urinary retention.</li><li>Skin — rash, photosensitivity.</li><li>Gastrointestinal — anorexia, gastric irritation, jaundice (rare).</li><li>Cardiovascular — palpitations, hypotension, arrhythmias.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">MHRA, 2017</a>]</p><!-- end field 83da138b-f44e-4b06-8871-a82c00a5cf46 --><!-- end item ef6c7372-2394-44b7-b5c5-a82c00a5cd9a -->","subChapters":[]},{"id":"40840f39-df16-5e24-86ed-cb080d5a12e9","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 147e8407-58e2-4335-97a6-a82c00a5e6c8 --><h3>What drug interactions occur with promethazine?</h3><!-- end field 147e8407-58e2-4335-97a6-a82c00a5e6c8 -->","summary":"","htmlStringContent":"<!-- begin item 133c9fb5-e39f-4eac-9f26-a82c00a5e51d --><!-- begin field ac827fab-c695-494e-8f6b-a82c00a5e6c8 --><ul><li>Drug interactions with promethazine include:<ul><li>Opioid analgesics — sedative effects may be enhanced when promethazine is given with opioid analgesics.</li><li>Alcohol — sedative effects may be increased by the combination of promethazine and alcohol.</li><li>Antimuscarinic drugs, tricyclic antidepressants, sedatives, and hypnotics — concomitant use with promethazine enhances the antimuscarinic and/or sedative action of these drugs.</li></ul></li><li>Promethazine has the potential to interact with immunological pregnancy tests (may give false-positive or false-negative results). It may also give a false negative result with skin tests by inhibiting the cutaneous histamine response — discontinue 72 hours in advance.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/vestibular-neuronitis/references/\">MHRA, 2017</a>]</p><!-- end field ac827fab-c695-494e-8f6b-a82c00a5e6c8 --><!-- end item 133c9fb5-e39f-4eac-9f26-a82c00a5e51d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}